Shingrix ( DrugBank: - )

3 diseases

46. 悪性関節リウマチ

臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03886038 (ClinicalTrials.gov)	March 15, 2019	2/1/2019	Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)	The Immunogenicity and Efficacy of Subunit Vaccine Against Herpes Zoster in RA Treated With JAK-inhibitors (VACCIMIL-ZOSTER)	Rheumatoid Arthritis;Healthy Controls	Biological: Shingrix	Region Skane	NULL	Recruiting	18 Years	N/A	All	150	Phase 4	Sweden

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03798691 (ClinicalTrials.gov)	May 28, 2019	2/1/2019	Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab	A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis;Herpes Zoster	Biological: Shingrix	University of Wisconsin, Madison	Boston Medical Center	Recruiting	50 Years	70 Years	All	30	Phase 4	United States

臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03591770 (ClinicalTrials.gov)	July 31, 2019	9/7/2018	Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib	The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib	Inflammatory Bowel Diseases	Biological: SHINGRIX	Boston Medical Center	NULL	Recruiting	50 Years	N/A	All	100	Phase 4	United States
2	NCT03798691 (ClinicalTrials.gov)	May 28, 2019	2/1/2019	Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab	A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis;Herpes Zoster	Biological: Shingrix	University of Wisconsin, Madison	Boston Medical Center	Recruiting	50 Years	70 Years	All	30	Phase 4	United States